Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146524 | 0.95 | LMNA (0.62) | USP5L3MBTL1KMT2ANR4A2LMNA | |
| SCHEMBL30089557 | 0.93 | PTGS1 (0.53) | USP5L3MBTL1KMT2ALMNAPTGS1 | |
| SCHEMBL8083048 | 0.84 | HSD17B3 (0.58) | L3MBTL1LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL9441163 | 0.84 | TRPA1 (0.53) | USP5KMT2ALMNASMN1; SMN2PTGS1 | |
| SCHEMBL14297902 | 0.84 | BLM (0.55) | USP5L3MBTL1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL29062360 | 0.83 | PTGS1 (0.45) | USP5L3MBTL1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9630906 | 0.82 | USP5 (0.55) | USP5L3MBTL1KMT2ANR4A2LMNA | |
| SCHEMBL9394922 | 0.82 | FAAH (0.51) | USP5KMT2ALMNASMN1; SMN2PTGS1 | |
| SCHEMBL11235329 | 0.81 | ACACB (0.60) | USP5L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL664336 | 0.81 | FFAR1 (0.61) | LMNAFFAR1PTGS1PTGS2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | disclosed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | USP5 3327/4885L3MBTL1 2958/4885KMT2A 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.